Ameriprise
MRVI icon

Ameriprise’s Maravai LifeSciences MRVI Stock Holding History

Ameriprise’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.31M Buy
210,062
+124,521
+146% +$538K ﹤0.01% 3285
2026
Q1 		$242K Buy
85,541
+71,912
+528% +$244K ﹤0.01% 3822
2025
Q4 		$44.3K Sell
13,629
-1,593,249
-99% -$5.36M ﹤0.01% 4046
2025
Q3 		$4.61M Sell
1,606,878
-16,625
-1% -$42.5K ﹤0.01% 2504
2025
Q2 		$3.91M Sell
1,623,503
-839,843
-34% -$1.77M ﹤0.01% 2538
2025
Q1 		$5.44M Sell
2,463,346
-1,148,279
-32% -$4.54M ﹤0.01% 2252
2024
Q4 		$19.7M Buy
3,611,625
+62,123
+2% +$400K 0.01% 1343
2024
Q3 		$29.5M Buy
3,549,502
+554,832
+19% +$4.8M 0.01% 1110
2024
Q2 		$21.4M Sell
2,994,670
-9,015
-0.3% -$77.8K 0.01% 1233
2024
Q1 		$26M Buy
3,003,685
+822,068
+38% +$5.56M 0.01% 1144
2023
Q4 		$14.3M Sell
2,181,617
-4,771
-0.2% -$30.8K ﹤0.01% 1480
2023
Q3 		$21.9M Buy
2,186,388
+511,387
+31% +$5.62M 0.01% 1164
2023
Q2 		$20.8M Buy
+1,675,001
New +$22.6M 0.01% 1229
2022
Q3 		– Sell
-53,995
Closed -$1.53M – 4005
2022
Q2 		$1.53M Sell
53,995
-49,151
-48% -$1.56M ﹤0.01% 2928
2022
Q1 		$3.64M Buy
103,146
+94,026
+1,031% +$3.15M ﹤0.01% 2624
2021
Q4 		$382K Sell
9,120
-373,238
-98% -$15.1M ﹤0.01% 3601
2021
Q3 		$18.8M Sell
382,358
-201,648
-35% -$9.84M 0.01% 1315
2021
Q2 		$24.4M Buy
584,006
+558,370
+2,178% +$21.6M 0.01% 1202
2021
Q1 		$913K Buy
25,636
+3,458
+16% +$115K ﹤0.01% 3182
2020
Q4 		$622K Buy
+22,178
New +$618K ﹤0.01% 3262

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
1WCM
12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OAM
Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Ameriprise's MRVI Position: Q2 2026 in Review

Ameriprise increased its Maravai LifeSciences (MRVI) stake by 146% in Q2 2026, buying an estimated $538K and bringing the position to 210,062 shares worth $1.31M. The position accounts for ﹤0.01% of the portfolio, ranked #3285.

Ameriprise first reported a position in MRVI in Q4 2020 and has held it in 20 quarters since. The position peaked at $29.5M in Q3 2024. 177 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

  • Ameriprise held 210,062 shares of Maravai LifeSciences worth $1.31M as of Q2 2026.
  • Ameriprise bought 124,521 Maravai LifeSciences shares in Q2 2026, an estimated $538K.
  • Maravai LifeSciences made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #3285 holding.
  • Ameriprise first reported a position in Maravai LifeSciences in Q4 2020 and has held it in 20 quarters since.
  • Ameriprise's Maravai LifeSciences position peaked at $29.5M in Q3 2024.
  • 177 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.